Chlorpheniramine
As of the edition of 20 October 2026, Chlorpheniramine is a small molecule: marketed, first approved in 1962 (ES); acts on HRH1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1991
- Kind
- Small molecule
- Brand name
- Contac
- First approved
- 1 April 1962 (ES)
- Approvals on record
- 41 in 4 regions
- Holder of the most recent approval
- Haleon; 19 holders in all
- Registered trials
- 13, 4 stopped early
- Disease areas
- Lungs and airways; Ear, nose and throat; Immune system; Infections; Digestive system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Chlorpheniramine.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 3 | 0 | 0 | 2 |
| Phase 3 | 4 | 1 | 1 | 2 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Applicant and Later holder | 1994 to now |
| GSK | Acquired holder | 2002 to now |
| Schering Plough Healthcare | Acquired holder | 2003 to now |
| Bayer | Acquired holder and Lead sponsor of trials | 2015 to now |
| Merck & Co. | Earlier holder |